By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    An Expert’s Guide To Building and Improving Endurance
    June 30, 2022
    medical assistants
    What Do Medical Assistants Do On a Day to Day Basis?
    April 5, 2022
    superfoods to help with prostate health
    10 Healthy Foods That Can Help Protect Your Prostate
    August 29, 2022
    Latest News
    Biohazard Cleanup: The Importance of Proper Disposal and Containment
    December 2, 2023
    Medicare Helps Seniors, and People with Disabilities & ESRD
    November 27, 2023
    The Link Between Allergies and Sinusitis & Strategies for Relief
    November 27, 2023
    What Health Complications Can a Sunburn Cause?
    November 22, 2023
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    Image
    Denying care? Concerns with Oregon’s Medicaid Coverage Guidelines
    September 30, 2013
    How Staffing Agencies are Helping Healthcare Professionals Land their Dream Jobs
    February 26, 2016
    Reducing Health Care Costs: Let’s Try What Has Worked
    October 16, 2013
    Latest News
    Automation in Pharmacovigilance: A Double-Edged Sword
    November 15, 2023
    What Does Science Say About Modern Health Practices?
    November 12, 2023
    Harnessing the Power of Email Marketing in Healthcare
    October 26, 2023
    10 Proven Strategies to Level Up Your Health Business
    October 25, 2023
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Through the Murky Slog: Part II—A New Light for Cancer Therapies?
Share
Sign In
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Have an existing account? Sign In
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > Medical Innovations > Through the Murky Slog: Part II—A New Light for Cancer Therapies?
BusinessDiagnosticsMedical InnovationsTechnology

Through the Murky Slog: Part II—A New Light for Cancer Therapies?

Shane Climie
Last updated: 2011/11/10 at 8:55 AM
Shane Climie
Share
4 Min Read
SHARE

Last week, we discussed new drug approvals that reflected a paradigm shift for cancer drug development and for treatment of people living with cancer. Finally, we are starting to see a matchup of specific diagnostics with targeted biotherapeutics to address (effectively, we hope) targeted treatments for smaller groups of cancer patients.

Last week, we discussed new drug approvals that reflected a paradigm shift for cancer drug development and for treatment of people living with cancer. Finally, we are starting to see a matchup of specific diagnostics with targeted biotherapeutics to address (effectively, we hope) targeted treatments for smaller groups of cancer patients.

Just recently, the American Society for Clinical Oncology (ASCO) urged the use of new biological knowledge to develop treatments faster, design more targeted clinical trials, and use information technology to integrate once-separate translational and clinical research. ASCO even says that targeted therapies can improve clinical trial responses from 8 to 30 percent. Also, just recently, the FDA gave itself a pat on the back as it highlighted its recent innovative drug approvals, with targeted cancer therapies included among those on the list.

What both of these events underscore is that we’re now finally seeing real co-development of drugs and companion diagnostics. This is a refreshing departure from the old system in which tests were developed after the drug was approved, often to rescue certain drugs that were facing rejection or had been pulled from the market.

We expect this trend to continue and will probably start to see new tests in two categories:

  1. Tests designed to include or to qualify patients. For example, if the specific drug target is present or activated, say, by a genetic alignment that creates the target (like Bcr-Abl fusion for leukemia), or mutations activate the target (like V600E in BRAF for melanoma), it will be sensitive to inhibitors.
  2. Tests designed to exclude or to disqualify patients. An example would be tests that determine the vicinity of the target pathway to determine if pre-existing mutations would enable the cancer to bypass drug activity (like KRAS mutations that circumvent EGFR inhibition).

While this may bring optimism to patients and investors alike, Ken Walz, my colleague at Popper and Co., has a warning:

“Don’t discount the economic impact of this new world of cancer therapies. Pharmaceutical companies will at first be hesitant to abandon their blockbuster strategy. Niche drugs would not be sustainable under their cost structure. If discovery and development costs stay the same, the price of niche drugs would have to be very, very high. But if ASCO’s goals come true, R&D costs could realistically come down. And a portfolio of niche drugs could work very well, indeed.”

Good food for thought, considering how many times that light at the end of the cancer therapy tunnel was just a reflection off more muck. What do you think? What does the future of cancer therapy look like? Or the future of pharmaceutical development and R&D investment, for that matter? Share your thoughts with us.


This post was originally published on the Popper and Co Blog. Shane Climie has more than 20 years of R&D and business development experience in the life sciences and pharmaceutical industry and is currently a principal at Popper and Co.

TAGGED: cancer, cancer drugs, cancer therapies, cancer treatment

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Shane Climie November 10, 2011 November 10, 2011
Share This Article
Facebook Twitter Copy Link Print
Share
Previous Article Adolescent Pregnancy
Next Article Medicare Has Lower Than Expected Premium Increases

Stay Connected

1.5k Followers Like
4.5k Followers Follow
2.8k Followers Pin
136k Subscribers Subscribe

Latest News

sublingual immunotherapy
Sublingual Immunotherapy: A Safe and Effective Alternative to Allergy Shots
Allergy Specialties December 2, 2023
Biohazard Cleanup: The Importance of Proper Disposal and Containment
Biohazard Cleanup: The Importance of Proper Disposal and Containment
Health December 2, 2023
Medical Device Concept Development Paving the Way for Healthcare Innovations
Medical Device Concept Development: Paving the Way for Healthcare Innovations
Medical Devices December 2, 2023
A Guide to Bioidentical Hormone Replacement Therapy (BHRT)
A Guide to Bioidentical Hormone Replacement Therapy (BHRT)
Therapies December 2, 2023

You Might also Like

Medical Device Concept Development Paving the Way for Healthcare Innovations
Medical Devices

Medical Device Concept Development: Paving the Way for Healthcare Innovations

December 2, 2023
healthcare business website
Technology

Choosing the Right Domain Name for Your Healthcare Business

November 27, 2023
healthcare software development
Technology

Shaping the Future of Healthcare Software Development

November 23, 2023
Modern Health Practices
Medical Innovations

What Does Science Say About Modern Health Practices?

November 12, 2023
Subscribe

Subscribe to our newsletter to get our newest articles instantly!

Follow US
© 2008-2023 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Lost your password?